RebeccaJeanneBrownMD

Pediatric Endocrinology • Bethesda, MD

Pediatric Bone Metabolism Disorders

Physician

Join to view full profile

Dr. Brown is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brown's full profile

Already have an account?

Office
10 Center Dr
10 Crc Room 1-3330, Msc 1103
Bethesda, MD 20892
Phone+1 301-496-4686

Fax+1 301-402-0574

Education & Training

National Institutes of Health Clinical Center/Eunice Kennedy Shriver NICHDFellowship, Pediatric Endocrinology, 2005 - 2008
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2002 - 2005
Mayo Clinic College of MedicineClass of 2002

Certifications & Licensure

MD State Medical License 2005 - 2026
OH State Medical License 2002 - 2005
American Board of Pediatrics Pediatric Endocrinology

Clinical Trials

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus Start of enrollment: 2011 Mar 31
Terminated
Phase 2
Metabolic Effects of Non-Nutritive Sweeteners Start of enrollment: 2010 Nov 04
Completed
Phase 1, Phase 2
Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations Start of enrollment: 2015 Apr 17
Completed
Phase 2
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Start of enrollment: 2014 Oct 09
RECRUITING
PHASE3
Roles: Principal Investigator, Contact
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) Start of enrollment: 2022 Feb 28
TERMINATED
PHASE2
Roles: Principal Investigator, Contact
Genetic Studies of Insulin and Diabetes Start of enrollment: 1976 Feb 01
RECRUITING
Roles: Principal Investigator, Contact
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance Start of enrollment: 2023 Jan 23
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Start of enrollment: 2022 Sep 07
RECRUITING
Roles: Principal Investigator, Contact
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD) Start of enrollment: 2024 Jan 03
RECRUITING
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy.
Yael Lebenthal, Sharon Halperin, Hagar Interator, Avivit Brener, Rebecca J Brown
Diabetes Care. 2025-03-19
1 citations
Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease.
Maiah Brush, Sungyoung Auh, Elaine Cochran, Rebecca Tuska, Christopher Koh
The Journal of Clinical Endocrinology and Metabolism. 2025-03-17
Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
Rasimcan Meral, Merve Celik Guler, Diarratou Kaba, Jeevitha Prativadi, Eric D Frontera
Diabetes Care. 2025-03-10

Lectures

Pubertal Gonadotropins Are Required for Insulin-induced Hyperandrogenism
Bethesda, MD - 6/14/2014
Clinical Effects of Metreleptin in Partial vs. Generalized Lipodystrophy: The Role of Baseline Abnormalities
Bethesda, MD - 6/15/2014
Comparison of Metabolic Characteristics in Patients with Generalized vs. Partial Lipodystrophy
Bethesda, MD - 6/15/2014

RebeccaJeanneBrownMD

Dr. Brown is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.